Summary of patients with breast lymphoma
| Patient | Age | 1°/2° | Side | Size (cm) | Biopsy | WHO type | Treatment | Survival (months) | Remission status/cause of death |
|---|---|---|---|---|---|---|---|---|---|
| *CNS involvement at relapse; †male patient; ‡insufficient material for immunohaematology/genetics. | |||||||||
| 1°, primary; 2°, secondary; APBSCT, autologous peripheral blood stem cell transplant; BCL NOS, B cell lymphoma not otherwise specified; C, core; CHOP, cyclophosphamide/adriamycin/vincristine/prednisolone; Cl, chlorambucil; CNS, central nervous system; CR, complete remission; CVP, cyclophosphamide/vincristine/prednisolone; DLBCL, diffuse large B cell lymphoma; E, excision; FC, fludarabine/cyclophosphamide; FCL, follicular cell lymphoma; It Mtx, intrathecal methotrexate; MCL, mantle cell lymphoma; MRD, minimal residual disease; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; P, prednisolone; SLL, small lymphocytic lymphoma; WHO, World Health Organisation; XRT, radiotherapy. | |||||||||
| 1 | 75 | 1° | Right | 2.5 | E | DLBCL | E | 13 | UD |
| 2 | 83 | 1° | Right | 8 | E | DLBCL* | E | 5 | NHL |
| 3 | 61 | 1° | Right | 5 | E | DLBCL | E+CHOP | 83 | NHL |
| 4 | 88 | 1° | Left | 3 | E | BCL NOS | E+P | 30 | UD |
| 5 | 67† | 1° | Right | 6 | C | DLBCL* | CHOP, It Mtx,CNS XRT | 18 | NHL |
| 6 | 66 | 1° | Left | 4 | E | DLBCL | CHOP, XRT | 34+ | CR |
| 7 | 62 | 1° | Right | 3.5 | E | DLBCL | E+CHOP, R+CHOP, APBSCT | 36+ | CR |
| 8 | 71 | 1° | Right | 2 1.5 | E | FCL | E+FC | 12+ | CR |
| 9 | 73 | 1° | Right | 1.8 | E | MZL | ND | ND | ND |
| 10‡ | 59 | 2° | Right | 1.5 | E | FCL (III) | E, Cl, CHOP APBSCT | 30 | NHL |
| 11 | 53 | 2° | Right | 4 | C | MCL (IV) | CHOP, APBSCT | 51+ | MRD |
| 12 | 75 | 2° | Left | 5 | C | DLBCL (IV) | R+P | 12 | NHL |
| 13 | 86 | 2° | Right | 1 | E | SLL | None | 13 | NHL |
| 14 | 78 | 2° | Left | 6 | C | BCL NOS (IV) | CVP | 4 | NHL |